Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study

Altamura, Alfredo Carlo; Salvadori, Daniele; Madaro, Donato; Santini, Annalisa; Mundo, Emanuela

doi:10.1016/s0165-0327(02)00075-7

Cited by 43 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This profile of safety and tolerability had already been described in previous case reports. 37,38 Although there 8 are case reports in the literature on induced mania in patients with schizoaffective disorder, 39,40 this effect was not observed in our case.…”

Section: Resultscontrasting

confidence: 50%

Uso de quetiapina em transtorno de humor bipolar de início precoce

Boarati

Cavalcanti

Fu‐I

2006

Rev. psiquiatr. Rio Gd. Sul

View full text Add to dashboard Cite

O transtorno do humor bipolar de início na infância e adolescência tornou-se um grande desafio aos profissionais que atendem a essa população, bem como a quem se dedica a estudá-la com mais profundidade. Primeiramente, isso se deve à dificuldade em se fechar o diagnóstico clínico e também em se estabelecer uma terapêutica medicamentosa eficaz, segura e permanente. Diferenças no padrão de ciclagem, predominância de fases mistas, gravidade das crises e a necessidade de se utilizar associações farmacológicas tornam o tratamento do transtorno bipolar de início precoce bastante complexo, exigindo uma gama maior de possibilidades terapêuticas. O caso apresentado relata a experiência com o uso da quetiapina em um paciente com o diagnóstico clínico de transtorno do humor bipolar de início na infância e adolescência, que começou aos 12 anos, e cuja resposta aos diferentes esquemas se mostrou insatisfatória. O uso da quetiapina mostrou-se eficaz no controle da crise e na estabilização do humor neste caso.

show abstract

Section: Resultscontrasting

confidence: 50%

Uso de quetiapina em transtorno de humor bipolar de início precoce

Boarati

Cavalcanti

Fu‐I

2006

Rev. psiquiatr. Rio Gd. Sul

View full text Add to dashboard Cite

show abstract

“…[28][29][30][31][32][33][34] However, the first step needed for successful treatment is proper diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life Among Bipolar Disorder Patients Misdiagnosed With Major Depressive Disorder

Ag¹,

Rajagopalan²,

Bolge³

et al. 2007

Prim. Care Companion J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: Bipolar disorder is frequently misdiagnosed as major depressive disorder (MDD). We aim to quantify the prevalence of misdiagnosed bipolar disorder among the depression population and evaluate the quality-of-life (QOL) impact of misdiagnoses.Method: Data were collected from 2 selfadministered, cross-sectional studies in 2003. Patients participating in The Bipolar Disorder Misdiagnosis Study (N = 1156) were previously diagnosed with depression, experienced a depressive episode within the past year, and had no previous diagnosis of bipolar disorder or schizophrenia. Patients who experienced a manic episode in the past year, based on DSM-IV criteria, were classified as misdiagnosed. Patients participating in The Bipolar Disorder Project (N = 1214) selfreported a diagnosis of bipolar disorder and were recruited through community mental health centers and support groups. Quality of life was assessed via the Psychological General Well-Being (PGWB) Index and Medical Outcomes Study 8-Item Short-Form Health Survey (SF-8). Demographic differences between groups were controlled using linear regression models.Results: Of the diagnosed MDD sample, 14.3% met criteria for misdiagnosed bipolar disorder. When controlling for demographic differences, the PGWB overall score for the misdiagnosed averaged 12.77 (p < .001) points lower than that of MDD patients and 9.55 (p < .001) points lower than that of diagnosed bipolar disorder patients. The average SF-8 mental component summary score for the misdiagnosed was 5.85 (p < .001) points lower than that of MDD patients and 3.18 (p = .002) points lower than that of diagnosed bipolar disorder patients.Conclusion: Misdiagnosis is associated with poorer QOL than MDD or diagnosed bipolar disorder, which are recognized as having a considerable impact on QOL.(Prim Care Companion J Clin Psychiatry 2007;9:195-202) ipolar disorder, a chronic affective disorder characterized by depression and at least 1 manic episode,

show abstract

“…In addition, QTP has partial agonist activity at serotonin 5-HT1A receptors. Recent studies have demonstrated that this atypical antipsychotic may be effective in the treatment of depressive symptoms associated with psychotic and mood disorders, including bipolar disorder I and II (Altamura et al, 2003;Ertugrul and Meltzer, 2003;Calabrese et al, 2005) and rapid cycling bipolar disorder (Vieta et al, 2002). The effectiveness of QTP in reverting depressive symptoms might be of particular interest because the presence of depression, more than positive and negative symptoms, markedly impairs the quality of life of schizophrenic patients during the stable period of the disease.…”

Section: Introductionmentioning

confidence: 99%

Quetiapine Prevents Anhedonia Induced by Acute or Chronic Stress

Orsetti

Canonico

Dellarole

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

The role of atypical antipsychotics as add-on treatments and as primary mood stabilizers in different phases of bipolar disorder is an important current research area. Although in bipolar patients the main therapeutic indication of quetiapine (QTP) is the management of acute mania, several observations suggest that this agent may exert antidepressant as well as antimanic effects. However, in our knowledge, there are no preclinical studies supporting this hypothesis. Thus, the main goal of the present work was to evaluate the putative antidepressant effect of QTP (0.4, 2.0, or 10 mg/kg/day), in comparison to amitriptyline (AMI) (2 or 5 mg/kg/day), in rats exposed to acute or chronic stress. The administration of QTP, 2 mg/kg/day, prevents the onset of anhedonia in rats exposed to a 6-week chronic mild stress (CMS) protocol. The effect of QTP has a slow onset, beginning at week 5, and causes a complete recovery from anhedonia. In this respect, the effect of QTP is similar to that obtained after chronic administration of AMI 2 or 5 mg/kg/day. Our findings also indicate that a 6-week administration of QTP, 2 or 10 mg/kg/day, has protective effects against the onset of anhedonia caused by the exposure to an acute subthreshold stressful event in rats that have previously experienced the CMS procedure. The results suggest that QTP is able to prevent both the transient mood depression caused by acute stress and the long-lasting anhedonic state induced by exposure, over a period of weeks, to a variety of unpredictable mild stressors.

show abstract

Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study

Cited by 43 publications

References 4 publications

Uso de quetiapina em transtorno de humor bipolar de início precoce

Uso de quetiapina em transtorno de humor bipolar de início precoce

Quality of Life Among Bipolar Disorder Patients Misdiagnosed With Major Depressive Disorder

Quetiapine Prevents Anhedonia Induced by Acute or Chronic Stress

Contact Info

Product

Resources

About